His protest was both a rejection of the idea that human life is expendable and an acknowledgment that, for so many, it ...

In this week's Current Climate newsletter, EPA's radical break with Republican history; a climate-friendly digital bank’s ...

"This is a historic moment for 4DMT as we become a Phase 3 company following our initiation of the 4FRONT-1 clinical trial,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.

An "embedding model" is an AI model that is used to turn characters, words, or sentences into a vector -- a group of ... Also: Want to win in the age of AI? You can either build it or build ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...

Operator Good morning, and welcome to Ocugen's fourth quarter and full-year 2024 financial results and business update.

Operator Good day, and welcome to MongoDB's Q4 fiscal year 2025 earnings call. At this time, all participants are in a listen ...

It’s not genetics, age or lack of exercise driving the rapid ... The goal, she said, is to study what she calls the leading vector of disease: corporations. Inside Climate News asked the ...

Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical ...